Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT [Yahoo! Finance]
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: Yahoo! Finance
Olema bounced back on Wednesday to hit a new four-year high as investors took heart from an investment firm's higher price target for its stock. At intra-day trading, Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) soared to its highest price of $30.97 before trimming gains to finish the day just up by 15.43 percent at $30.68 apiece. In a market report, Jefferies raised its price target for the company to $43 from $30 previously, marking a 40 percent upside potential from its latest closing price. The upgrade reflected the investment firm's confidence in oral Selective Estrogen Receptor Degrader (SERD), supported by Roche's encouraging results from the phase 3 trial of giredestrant in the treatment of breast cancer. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is also underway with the clinical trial for its own breast cancer therapy called palazestrant. According to Jefferies, the strong performance of next-generation oral SERDs as compared with standard endocrine therapy continues
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at Citigroup Inc. from $21.00 to $60.00. They now have a "buy" rating on the stock.MarketBeat
- Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $45.00 to $48.00. They now have an "outperform" rating on the stock.MarketBeat
- Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $26.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at HC Wainwright from $36.00 to $45.00. They now have a "buy" rating on the stock.MarketBeat
- Roche boosts Olema after additional late-stage trial data for breast cancer drug [Seeking Alpha]Seeking Alpha
OLMA
Earnings
- 11/10/25 - Miss
OLMA
Sec Filings
- 12/11/25 - Form S-3ASR
- 12/9/25 - Form 4
- 12/1/25 - Form 4
- OLMA's page on the SEC website